Analytical Data
-
基因名
FGFR-3 alpha (IIIb)
-
简介
The FGFR-3 protein is a tyrosine-protein kinase receptor for fibroblast growth factor that is critical for cellular processes, particularly in chondrocytes, osteoblasts, and inner ear development. Its effects span normal skeletal development and postnatal bone mineralization. FGFR-3 alpha (IIIb) Protein, Human (HEK293, His-Avi) is the recombinant human-derived FGFR-3 alpha, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
别名
ACH; CD333; CEK; CEK2; EC 2.7.10; FGF R3; FGFR3; HSFGFR3EX; JTK4
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P22607-2
-
表达区间
E23-G377
-
蛋白长度
Partial
-
分子量
65-75 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast Growth Factor Receptor 3 (FGFR3) is a key player in various cellular processes, including growth, differentiation, and tissue repair. It is part of the FGFR family, which consists of four members, and is primarily associated with skeletal development and homeostasis. FGFR3 harbors specific isoforms, with the alpha (IIIb) form being particularly significant due to its expression patterns in different tissues. Mutations in the FGFR3 gene are linked to a range of skeletal disorders, including achondroplasia and thanatophoric dysplasia. These mutations often lead to aberrant signaling pathways, resulting in impaired bone growth and development. Research into FGFR3 alpha (IIIb) recombinant proteins has garnered attention for the potential development of targeted therapies to mitigate the effects of these mutations. By producing and studying the recombinant form of FGFR3 alpha (IIIb), scientists aim to better understand its functional roles and the molecular mechanisms underlying related pathologies. Furthermore, investigating the protein's interactions and downstream signaling pathways could pave the way for novel therapeutic approaches, such as small molecules or monoclonal antibodies, aiming to correct or compensate for the dysregulated signaling caused by FGFR3 mutations. Overall, the study of FGFR3 alpha (IIIb) recombinant protein holds promise for advancing knowledge in developmental biology and for developing clinical strategies to treat FGFR-related disorders.
